HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DUALITYBIO-B

197.500

+14.2007.75%

Volume:1.73M

Turnover:337.52M

Market Cap:17.94B

PE:-4.23

High:200.200

Open:183.700

Low:183.700

Close:183.300

52wk High:451.200

52wk Low:158.500

Shares:90.83M

HK Float Shares:90.83M

Volume Ratio:1.99

T/O Rate:1.91%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-46.640

ROE:-65.93%

ROA:-24.28%

PB:10.55

PE(LYR):-4.23

PS:18.18

Loading ...

Overview Company News Filings

Stock Track | DUALITYBIO-B Soars 5.02% Intraday on STAR Market Listing Plan Announcement

DualityBio-B Advances Global ADC Leadership with Dual Capital Platform Strategy

DualityBio Convenes 29 April 2026 EGM to Approve RMB Share Issue and Corporate Governance Amendments

Bulletin Express

Duality Biotherapeutics announces extraordinary general meeting

DualityBio Proposes Up to RMB 6.75 Billion STAR Market IPO; Shareholders to Vote on 29 April 2026

Bulletin Express

BRIEF-Duality Biotherapeutics Approved Proposed RMB Share Issue On Sci-Tech Board

DUALITYBIO-B Plans RMB Share Issuance for STAR Market Listing, Targeting Up to 6.75 Billion Yuan

Duality Biotherapeutics Inc - Proceeds Raised From RMB Share Issue Will Be Used for Innovative Drug Research, Others

THOMSON REUTERS

Duality Biotherapeutics Inc - Approved Proposed RMB Share Issue on Sci-Tech Board

THOMSON REUTERS

Duality Biotherapeutics Inc - Proposes to Issue Not More Than 15.8 Mln RMB Shares

THOMSON REUTERS

DualityBio says China NMPA accepts trastuzumab pamirtecan breast cancer BLA for review

Dualitybio Announces China Nmpa Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic Her2-Positive Adult Breast Cancer

THOMSON REUTERS

DUALITYBIO-B's New Drug Application for HER2-Positive Breast Cancer Accepted by NMPA

BRIEF-Duality Biotherapeutics Says NMPA Accepts Biologics License Application For Db-1303/Bnt323

Duality Biotherapeutics Inc - Nmpa Accepts Biologics License Application for Db-1303/Bnt323 in Her2-Positive Breast Cancer

THOMSON REUTERS

Duality Biotherapeutics says China NMPA accepts BLA for DB-1303 in HER2+ breast cancer

Duality Biotherapeutics Sets 24–29 April 2026 Book Closure for Extraordinary General Meeting

Bulletin Express

Duality Biotherapeutics announces extraordinary general meeting

HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio Up 7%; Hengrui Pharma And Junshi Bio Up 6%; HBM, Beigene, Sihuan Pharm Up 5%

Tiger Newspress

DualityBio-B Maintains Outperform Rating with HK$430 Target from CICC

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/09606/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09606","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09606\",,,,,undefined,":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"DUALITYBIO-B","latestPrice":197.5,"timestamp":1789718912007,"preClose":183.3,"halted":0,"volume":1731467,"delay":0,"changeRate":0.07746863066011996,"floatShares":90833600,"shares":90833600,"eps":-46.640351785602206,"marketStatus":"Market Closed","change":14.2,"latestTime":"09-18 16:08:32","open":183.7,"high":200.2,"low":183.7,"amount":337516438,"amplitude":0.090016,"askPrice":197.5,"askSize":4800,"bidPrice":195.8,"bidSize":16800,"shortable":3,"etf":0,"ttmEps":-18.883646022163123,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789954200000},"marketStatusCode":7,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":183.3,"openAndCloseTimeList":[[1789695000000,1789704000000],[1789707600000,1789718400000]],"volumeRatio":1.991515510767703,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09606\",,,,,undefined,":{"symbol":"09606","floatShares":90833600,"roa":"-24.28%","roe":"-65.93%","lyrEps":-46.640352,"volumeRatio":1.991515510767703,"shares":90833600,"dividePrice":0,"high":200.2,"amplitude":0.090016,"preClose":183.3,"low":183.7,"week52Low":158.5,"pbRate":"10.55","psRate":"18.18","week52High":451.2,"institutionHeld":0,"latestPrice":197.5,"committee":0.555556,"eps":-46.640351785602206,"divideRate":0,"volume":1731467,"delay":0,"ttmEps":-18.883646022163123,"open":183.7,"prevYearClose":298.2,"prevWeekClose":168.7,"prevMonthClose":184.3,"prevQuarterClose":181.2,"fiveDayClose":168.7,"twentyDayClose":194.5,"sixtyDayClose":168.1},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09606\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"09606","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787880600000,"name":null,"time":"","dateTimestamp":1787846400000,"actualEps":null},{"date":"2026-03-23","symbol":"09606","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774229400000,"name":null,"time":"","dateTimestamp":1774195200000,"actualEps":null},{"date":"2025-08-26","symbol":"09606","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09606\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09606\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.5714,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":7,"updateTime":1786723200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09606\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09606","date":"2026-09-17","current":-10.458785,"percent":0.361823,"low":-29.984477,"twenty":-16.019043,"median":-9.342917,"eighty":-6.847901,"high":-4.703556,"avg":-11.518791,"sd":6.115194,"marketCap":16580000806},"quantilePoints":[{"date":"2025-04-17","current":-14.905978,"twenty":-15.065639,"median":-14.442293,"eighty":-11.334487,"marketCap":16635152800},{"date":"2025-04-25","current":-15.846935,"twenty":-16.770434,"median":-15.576033,"eighty":-14.349556,"marketCap":17719522633},{"date":"2025-05-02","current":-16.438538,"twenty":-16.715855,"median":-16.124153,"eighty":-14.985809,"marketCap":18420101638},{"date":"2025-05-09","current":-15.074661,"twenty":-16.551291,"median":-15.826729,"eighty":-15.074661,"marketCap":17010399982},{"date":"2025-05-16","current":-15.043786,"twenty":-16.438538,"median":-15.220044,"eighty":-14.405796,"marketCap":17114249721},{"date":"2025-05-23","current":-16.495727,"twenty":-16.438538,"median":-15.262587,"eighty":-14.582474,"marketCap":18822153243},{"date":"2025-05-30","current":-16.208434,"twenty":-16.401371,"median":-15.460562,"eighty":-14.726132,"marketCap":18575651704},{"date":"2025-06-06","current":-16.427701,"twenty":-16.438538,"median":-15.666395,"eighty":-14.905978,"marketCap":18874975001},{"date":"2025-06-13","current":-20.940103,"twenty":-16.693343,"median":-15.893657,"eighty":-15.005253,"marketCap":24069114577},{"date":"2025-06-20","current":-18.479443,"twenty":-18.428819,"median":-16.104695,"eighty":-15.043786,"marketCap":21199132371},{"date":"2025-06-27","current":-18.0452,"twenty":-18.863356,"median":-16.282988,"eighty":-15.074661,"marketCap":20758951051},{"date":"2025-07-04","current":-21.227749,"twenty":-18.942282,"median":-16.427701,"eighty":-15.074735,"marketCap":24421259633},{"date":"2025-07-11","current":-22.045806,"twenty":-19.683704,"median":-16.508309,"eighty":-15.190609,"marketCap":25336836779},{"date":"2025-07-18","current":-25.758166,"twenty":-20.839221,"median":-16.693343,"eighty":-15.21995,"marketCap":29580184704},{"date":"2025-07-25","current":-25.970367,"twenty":-21.539184,"median":-16.981252,"eighty":-15.260218,"marketCap":29932329760},{"date":"2025-08-01","current":-24.963588,"twenty":-22.267132,"median":-18.096065,"eighty":-15.298157,"marketCap":28594178547},{"date":"2025-08-08","current":-27.998627,"twenty":-24.402884,"median":-18.454131,"eighty":-15.429476,"marketCap":32150843612},{"date":"2025-08-15","current":-27.487815,"twenty":-25.397092,"median":-18.863356,"eighty":-15.513126,"marketCap":31516982512},{"date":"2025-08-22","current":-26.341915,"twenty":-25.761111,"median":-19.052333,"eighty":-15.750472,"marketCap":30108402288},{"date":"2025-08-29","current":-8.977182,"twenty":-25.761111,"median":-19.118727,"eighty":-15.513126,"marketCap":27784244918},{"date":"2025-09-05","current":-10.341403,"twenty":-25.547361,"median":-18.897362,"eighty":-15.21995,"marketCap":31974771084},{"date":"2025-09-12","current":-12.806892,"twenty":-25.484142,"median":-18.479443,"eighty":-15.036079,"marketCap":39669140558},{"date":"2025-09-19","current":-11.291493,"twenty":-25.397092,"median":-18.151913,"eighty":-14.569138,"marketCap":34950396808},{"date":"2025-09-26","current":-9.575685,"twenty":-25.265241,"median":-17.183112,"eighty":-14.242848,"marketCap":29562577451},{"date":"2025-10-03","current":-9.769092,"twenty":-25.225948,"median":-16.756996,"eighty":-13.467837,"marketCap":30231653057},{"date":"2025-10-10","current":-8.39875,"twenty":-25.201143,"median":-16.551291,"eighty":-12.508489,"marketCap":25953090627},{"date":"2025-10-17","current":-9.52866,"twenty":-25.090759,"median":-16.467132,"eighty":-11.127698,"marketCap":29421719428},{"date":"2025-10-24","current":-8.24833,"twenty":-24.683236,"median":-16.401371,"eighty":-10.383008,"marketCap":25477694801},{"date":"2025-10-31","current":-8.936138,"twenty":-24.228898,"median":-16.208434,"eighty":-10.01166,"marketCap":27643386896},{"date":"2025-11-07","current":-8.115895,"twenty":-24.0933,"median":-15.983588,"eighty":-9.661913,"marketCap":25090335240},{"date":"2025-11-14","current":-9.615008,"twenty":-24.036348,"median":-15.846935,"eighty":-9.533336,"marketCap":29809078990},{"date":"2025-11-21","current":-8.88084,"twenty":-23.659864,"median":-15.493415,"eighty":-9.411746,"marketCap":27520136126},{"date":"2025-11-28","current":-9.805814,"twenty":-23.032171,"median":-15.270261,"eighty":-9.358381,"marketCap":30496838785},{"date":"2025-12-05","current":-9.522579,"twenty":-22.810207,"median":-15.147164,"eighty":-9.358381,"marketCap":29666872704},{"date":"2025-12-12","current":-9.227769,"twenty":-22.078047,"median":-15.043786,"eighty":-9.232281,"marketCap":28801588916},{"date":"2025-12-19","current":-9.562517,"twenty":-22.024358,"median":-14.816055,"eighty":-9.195431,"marketCap":29916743432},{"date":"2025-12-24","current":-8.86445,"twenty":-21.960012,"median":-14.582474,"eighty":-9.185632,"marketCap":27819193982},{"date":"2026-01-02","current":-8.361415,"twenty":-21.780535,"median":-14.405796,"eighty":-9.071858,"marketCap":26343799029},{"date":"2026-01-09","current":-10.158481,"twenty":-21.573184,"median":-14.143758,"eighty":-9.138635,"marketCap":32085396254},{"date":"2026-01-16","current":-10.130227,"twenty":-21.338723,"median":-13.671075,"eighty":-9.159542,"marketCap":32100133626},{"date":"2026-01-23","current":-9.450777,"twenty":-21.128733,"median":-12.833558,"eighty":-9.159542,"marketCap":29918397524},{"date":"2026-01-30","current":-9.27281,"twenty":-20.989151,"median":-11.556174,"eighty":-9.159542,"marketCap":29489203537},{"date":"2026-02-06","current":-8.834279,"twenty":-20.864442,"median":-11.154997,"eighty":-9.026205,"marketCap":28165855410},{"date":"2026-02-13","current":-9.445101,"twenty":-20.730279,"median":-10.443288,"eighty":-9.076015,"marketCap":30286271904},{"date":"2026-02-20","current":-9.824687,"twenty":-20.674464,"median":-10.43817,"eighty":-9.09489,"marketCap":31458062186},{"date":"2026-02-27","current":-8.771359,"twenty":-20.006759,"median":-10.305855,"eighty":-9.047703,"marketCap":28393379910},{"date":"2026-03-06","current":-8.859488,"twenty":-19.896232,"median":-10.18539,"eighty":-8.969972,"marketCap":28447462538},{"date":"2026-03-13","current":-7.555838,"twenty":-19.630572,"median":-10.144354,"eighty":-8.935093,"marketCap":24373237865},{"date":"2026-03-20","current":-7.859442,"twenty":-19.432697,"median":-9.991099,"eighty":-8.867218,"marketCap":25256587462},{"date":"2026-03-27","current":-8.718949,"twenty":-19.118727,"median":-9.951719,"eighty":-8.854358,"marketCap":25617138318},{"date":"2026-04-02","current":-9.880216,"twenty":-19.012497,"median":-9.885599,"eighty":-8.850342,"marketCap":29168564250},{"date":"2026-04-10","current":-9.180446,"twenty":-18.964111,"median":-9.878849,"eighty":-8.85641,"marketCap":27311727342},{"date":"2026-04-17","current":-9.417233,"twenty":-18.904163,"median":-9.820225,"eighty":-8.842311,"marketCap":28027927148},{"date":"2026-04-24","current":-8.878352,"twenty":-18.860571,"median":-9.805814,"eighty":-8.846908,"marketCap":26425587896},{"date":"2026-04-30","current":-8.372511,"twenty":-18.781003,"median":-9.783435,"eighty":-8.82699,"marketCap":24926391864},{"date":"2026-05-08","current":-7.738947,"twenty":-18.469318,"median":-9.736996,"eighty":-8.785939,"marketCap":23120131584},{"date":"2026-05-15","current":-6.609967,"twenty":-18.384608,"median":-9.691452,"eighty":-8.751075,"marketCap":20699742808},{"date":"2026-05-22","current":-6.440114,"twenty":-18.185423,"median":-9.652725,"eighty":-8.708072,"marketCap":20121739519},{"date":"2026-05-29","current":-6.506712,"twenty":-18.096065,"median":-9.620334,"eighty":-8.669056,"marketCap":20400514838},{"date":"2026-06-05","current":-5.374082,"twenty":-18.0452,"median":-9.575685,"eighty":-8.511806,"marketCap":16873830092},{"date":"2026-06-12","current":-5.36331,"twenty":-17.183112,"median":-9.557279,"eighty":-8.481744,"marketCap":16828616185},{"date":"2026-06-18","current":-5.321722,"twenty":-16.860136,"median":-9.537613,"eighty":-8.412993,"marketCap":16738188371},{"date":"2026-06-26","current":-4.703556,"twenty":-16.761475,"median":-9.522579,"eighty":-8.375473,"marketCap":14721648119},{"date":"2026-07-03","current":-6.212828,"twenty":-16.718804,"median":-9.508222,"eighty":-8.310046,"marketCap":19460065572},{"date":"2026-07-10","current":-6.457487,"twenty":-16.608112,"median":-9.462457,"eighty":-8.218812,"marketCap":20201573647},{"date":"2026-07-17","current":-6.192643,"twenty":-16.533051,"median":-9.445101,"eighty":-8.097368,"marketCap":19441980010},{"date":"2026-07-24","current":-6.744145,"twenty":-16.505793,"median":-9.428231,"eighty":-7.995787,"marketCap":21178194038},{"date":"2026-07-31","current":-5.225281,"twenty":-16.472851,"median":-9.409879,"eighty":-7.856069,"marketCap":16439776585},{"date":"2026-08-07","current":-5.555188,"twenty":-16.434203,"median":-9.398864,"eighty":-7.73561,"marketCap":17511664790},{"date":"2026-08-14","current":-5.519506,"twenty":-16.417169,"median":-9.342917,"eighty":-7.473767,"marketCap":17421211976},{"date":"2026-08-21","current":-5.561665,"twenty":-16.354018,"median":-9.310353,"eighty":-6.918832,"marketCap":17593072323},{"date":"2026-08-28","current":-5.723357,"twenty":-16.253166,"median":-9.270261,"eighty":-6.767757,"marketCap":18108653362},{"date":"2026-09-04","current":-9.738306,"twenty":-16.191745,"median":-9.310353,"eighty":-6.781144,"marketCap":16344823489},{"date":"2026-09-11","current":-9.079348,"twenty":-16.117099,"median":-9.324437,"eighty":-6.805148,"marketCap":15259389721},{"date":"2026-09-17","current":-9.85224,"twenty":-16.019043,"median":-9.342917,"eighty":-6.847901,"marketCap":16580000806}],"updateTime":1789763090690},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09606\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1170833307","title":"Stock Track | DUALITYBIO-B Soars 5.02% Intraday on STAR Market Listing Plan Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1170833307","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170833307?lang=en_us&edition=fundamental","pubTime":"2026-04-15 09:33","pubTimestamp":1776216839,"startTime":"0","endTime":"0","summary":"DUALITYBIO-B's stock price surged 5.02% during intraday trading on Wednesday, following the company's announcement of plans to pursue a secondary listing on China's STAR Market. The biopharmaceutical...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172774249","title":"DualityBio-B Advances Global ADC Leadership with Dual Capital Platform Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=1172774249","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172774249?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:03","pubTimestamp":1776211396,"startTime":"0","endTime":"0","summary":"On the evening of April 13, leading ADC company DualityBio-B (09606) announced that its board of directors has approved a plan to issue RMB-denominated shares and list on the STAR Market. The company...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","09606","HK0000500386.USD","LU2543165471.USD","BK1161","HK0000252152.HKD","BK4080","ADC","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154397574","title":"DualityBio Convenes 29 April 2026 EGM to Approve RMB Share Issue and Corporate Governance Amendments","url":"https://stock-news.laohu8.com/highlight/detail?id=1154397574","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154397574?lang=en_us&edition=fundamental","pubTime":"2026-04-14 21:21","pubTimestamp":1776172912,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics, Inc. (DualityBio) has issued a proxy form ahead of an Extraordinary General Meeting (EGM) scheduled for 9:00 a.m. on 29 April 2026 at its Shanghai headquarters, Board Room,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627441870","title":"Duality Biotherapeutics announces extraordinary general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2627441870","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627441870?lang=en_us&edition=fundamental","pubTime":"2026-04-14 21:04","pubTimestamp":1776171885,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics will hold an extraordinary general meeting in Shanghai on April 29, 2026.Shareholders will vote on a proposed RMB share issue, including a specific mandate to issue up to 15,779,190 RMB shares.Resolutions also cover board authorizations tied to the RMB share issue, use of proceeds, accumulated loss arrangements, and post-issue price stabilization and dividend return plans.Meeting agenda includes adoption of new procedural rules for shareholder meetings and board meetings, effective upon listing of RMB shares on the Sci-Tech Board.A special resolution seeks approval of amendments to articles of association, conditional on passage of the RMB share issue mandate.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duali","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL9cLHyq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","HK0000252160.HKD","09606","BK1161","LU2543165471.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189252112","title":"DualityBio Proposes Up to RMB 6.75 Billion STAR Market IPO; Shareholders to Vote on 29 April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1189252112","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189252112?lang=en_us&edition=fundamental","pubTime":"2026-04-14 21:04","pubTimestamp":1776171848,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics Inc. (DualityBio) has called an extraordinary general meeting for 29 April 2026 to seek approval for a domestic initial public offering of up to 15.78 million RMB-denominated...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627451061","title":"BRIEF-Duality Biotherapeutics Approved Proposed RMB Share Issue On Sci-Tech Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2627451061","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627451061?lang=en_us&edition=fundamental","pubTime":"2026-04-13 23:16","pubTimestamp":1776093384,"startTime":"0","endTime":"0","summary":"BRIEF-Duality Biotherapeutics Approved Proposed RMB Share Issue On Sci-Tech BoardApril 13  - Duality Biotherapeutics 9606.HK:APPROVED PROPOSED RMB SHARE ISSUE ON SCI-TECH BOARDPROPOSES TO ISSUE NOT MORE THAN 15.8 MILLION RMB SHARESPROCEEDS RAISED FROM RMB SHARE ISSUE WILL BE USED FOR INNOVATIVE DRUG RESEARCH, OTHERSFurther company coverage: 9606.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nFWN40W0VT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","LU2543165471.USD","BK1161","HK0000500386.USD","HK0000252160.HKD","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172062646","title":"DUALITYBIO-B Plans RMB Share Issuance for STAR Market Listing, Targeting Up to 6.75 Billion Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1172062646","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172062646?lang=en_us&edition=fundamental","pubTime":"2026-04-13 22:50","pubTimestamp":1776091843,"startTime":"0","endTime":"0","summary":"DUALITYBIO-B (09606) has announced that on April 13, 2026, its board of directors approved a proposed issuance of RMB-denominated shares for listing on the STAR Market, a special authorization, and...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","LU2543165471.USD","BK1161","09606","HK0000500386.USD","HK0000252160.HKD","159982","CYB","MUCmain","CNHmain","UCmain","HK0000252152.HKD","MCNHmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627513644","title":"Duality Biotherapeutics Inc - Proceeds Raised From RMB Share Issue Will Be Used for Innovative Drug Research, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2627513644","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627513644?lang=en_us&edition=fundamental","pubTime":"2026-04-13 22:41","pubTimestamp":1776091281,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nFWN40W0VT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09606","HK0000252160.HKD","HK0000252152.HKD","LU2543165471.USD","HK0000500386.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627513354","title":"Duality Biotherapeutics Inc - Approved Proposed RMB Share Issue on Sci-Tech Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2627513354","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627513354?lang=en_us&edition=fundamental","pubTime":"2026-04-13 22:41","pubTimestamp":1776091281,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nFWN40W0VT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2543165471.USD","09606","BK1161","HK0000500386.USD","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627451336","title":"Duality Biotherapeutics Inc - Proposes to Issue Not More Than 15.8 Mln RMB Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2627451336","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627451336?lang=en_us&edition=fundamental","pubTime":"2026-04-13 22:41","pubTimestamp":1776091281,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nFWN40W0VT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000252160.HKD","HK0000252152.HKD","BK1161","HK0000500386.USD","09606","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626219475","title":"DualityBio says China NMPA accepts trastuzumab pamirtecan breast cancer BLA for review","url":"https://stock-news.laohu8.com/highlight/detail?id=2626219475","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626219475?lang=en_us&edition=fundamental","pubTime":"2026-04-10 19:24","pubTimestamp":1775820278,"startTime":"0","endTime":"0","summary":"DualityBio said China NMPA accepted for review its BLA for trastuzumab pamirtecan  in HER2-positive unresectable or metastatic breast cancer.Filing seeks approval as second-line therapy versus Roche’s Kadcyla , based on interim Phase III data showing a statistically significant progression-free survival benefit.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire  on April 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL9PtyL1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","LU2543165471.USD","BK1161","HK0000252160.HKD","HK0000500386.USD","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626812591","title":"Dualitybio Announces China Nmpa Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic Her2-Positive Adult Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2626812591","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626812591?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:56","pubTimestamp":1775735770,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUA9T0R2M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000500386.USD","HK0000252152.HKD","HK0000252160.HKD","BK1161","09606","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150883471","title":"DUALITYBIO-B's New Drug Application for HER2-Positive Breast Cancer Accepted by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1150883471","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150883471?lang=en_us&edition=fundamental","pubTime":"2026-04-09 18:54","pubTimestamp":1775732071,"startTime":"0","endTime":"0","summary":"DUALITYBIO-B (09606) has announced that its Biologics License Application (BLA) for DB-1303/BNT323 has been accepted by the National Medical Products Administration (NMPA). This submission is based...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","HK0000500386.USD","IPOS","BK4585","DB","BK4566","BK1161","BK4588","LU2543165471.USD","HK0000252160.HKD","BK4552","BK4118","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626186811","title":"BRIEF-Duality Biotherapeutics Says NMPA Accepts Biologics License Application For Db-1303/Bnt323","url":"https://stock-news.laohu8.com/highlight/detail?id=2626186811","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626186811?lang=en_us&edition=fundamental","pubTime":"2026-04-09 18:53","pubTimestamp":1775731991,"startTime":"0","endTime":"0","summary":"BRIEF-Duality Biotherapeutics Says NMPA Accepts Biologics License Application For Db-1303/Bnt323April 9  - Duality Biotherapeutics Inc 9606.HK:NMPA ACCEPTS BIOLOGICS LICENSE APPLICATION FOR DB-1303/BNT323 IN HER2-POSITIVE BREAST CANCERFurther company coverage: 9606.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nFWN40S0CC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","HK0000252152.HKD","BK1161","09606","LU2543165471.USD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626518507","title":"Duality Biotherapeutics Inc - Nmpa Accepts Biologics License Application for Db-1303/Bnt323 in Her2-Positive Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2626518507","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626518507?lang=en_us&edition=fundamental","pubTime":"2026-04-09 18:49","pubTimestamp":1775731759,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nFWN40S0CC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2543165471.USD","BK1161","09606","HK0000500386.USD","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626185005","title":"Duality Biotherapeutics says China NMPA accepts BLA for DB-1303 in HER2+ breast cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2626185005","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626185005?lang=en_us&edition=fundamental","pubTime":"2026-04-09 18:49","pubTimestamp":1775731759,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics secured NMPA acceptance of biologics license application for DB-1303/BNT323 in unresectable or metastatic HER2-positive breast cancer in adults.Filing was supported by Phase III DB-1303-O-3001 data showing statistically significant progression-free survival improvement versus Roche’s Kadcyla .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL7bhTxC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","HK0000252152.HKD","BK1161","09606","LU2543165471.USD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172387094","title":"Duality Biotherapeutics Sets 24–29 April 2026 Book Closure for Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1172387094","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172387094?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:41","pubTimestamp":1775724115,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics, Inc. will convene an Extraordinary General Meeting (EGM) at 9:00 a.m. on Wednesday, 29 April 2026, in the Board Room, 11/F, Building A, No. 868 Yinghua Road, Pudong New Area,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626027389","title":"Duality Biotherapeutics announces extraordinary general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2626027389","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626027389?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:38","pubTimestamp":1775723893,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics scheduled an extraordinary general meeting in Shanghai on April 29, 2026.Share register closure set for April 24–29, 2026 to determine shareholder eligibility for the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL2Cgwcs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252160.HKD","HK0000252152.HKD","LU2543165471.USD","09606","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149528263","title":"HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio Up 7%; Hengrui Pharma And Junshi Bio Up 6%; HBM, Beigene, Sihuan Pharm Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1149528263","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149528263?lang=en_us&edition=fundamental","pubTime":"2026-03-27 14:14","pubTimestamp":1774592089,"startTime":"0","endTime":"0","summary":"HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio up 7%; Hengrui Pharma and Junshi Bio Up 6%; HBM, Beigene, $Sihuan Pharm(00460)$ Up 5%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","02359","02137","03759","09995","09688","01672","02269","09606","02268","02157","01093","01276","06606","09966","03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139469969","title":"DualityBio-B Maintains Outperform Rating with HK$430 Target from CICC","url":"https://stock-news.laohu8.com/highlight/detail?id=1139469969","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139469969?lang=en_us&edition=fundamental","pubTime":"2026-03-27 10:36","pubTimestamp":1774578988,"startTime":"0","endTime":"0","summary":"CICC has reiterated its Outperform rating on DUALITYBIO-B (09606) with an unchanged target price of HK$430, implying a 63.4% upside potential from the current share price, based on a DCF valuation...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252152.HKD","HK0000500386.USD","LU2543165471.USD","09606","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":7,"totalSize":158,"code":"91000000","status":"200"}]}}